Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Lviv Regional AIDS Health Center | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Contradicting preliminary results are available on the impact of COVID-19 in people with HIV (PWH). How achieving goals of the HIV 90-90-90 cascade of care influences the risk of COVID-19 in PWH is unclear. The primary objective is to determine the impact of COVID-19 in PWH cohorts from Ukraine and the Netherlands.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ATHENA | Cohort of people living with HIV in the Netherlands | ||
| LUKCY | Cohort of people living with HIV in the Lviv area, Ukraine |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence COVID19 | Prevalence (percent) of clinical COVID-19 in PWH cohorts from Ukraine and in the Netherlands. | Up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence COVID-19 | Incidence (nr cases/person years) of clinical COVID-19 cases in PWH cohorts from Ukraine and in the Netherlands | Up to 2 years |
| WHO categories COVID-19 | Prevalence of no suspicion, possible, probable and proven COVID-19 cases in the past 6 months PWH cohorts from Ukraine and the Netherlands. |
| Measure | Description | Time Frame |
|---|---|---|
| HIV vs non-HIV | Correlation of HIV status with the highest score on an ordinal scale for COVID-19 severity according to the adapted 5point WHO severity scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal) in matched PWH cases with HIV uninfected controls by age, sex and comorbidities. | Up to 2 years |
Inclusion Criteria:
HIV infected No registered objection to use of data
Exclusion Criteria:
None
Not provided
Not provided
Not provided
Not provided
People with HIV from patient cohorts in the Netherlands and Ukraine. All participants will be systematically included consecutively.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Erasmus MC | Rotterdam | 3015 CN | Netherlands | |||
| Lviv Regional AIDS Health Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38318789 | Derived | Vasylyev M, Buhiichyk V, Buhiichyck N, Groenendijk A, Ben I, Ostapiuk L, Sluzhynska M, Bierman WFW, van Kampen JJA, Wit FWNM, Reiss P, Rijnders BJA, Sluzhynska O, Rokx C. COVID-19 epidemiology and performance of the WHO clinical algorithm to diagnose COVID-19 in people with HIV from Ukraine. Int J STD AIDS. 2024 Jun;35(7):510-515. doi: 10.1177/09564624241231016. Epub 2024 Feb 6. |
Not provided
Not provided
Other research group can contact the PI with a research question to gain access to IPD.
Data will be kept up to 15 years
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Dec 7, 2023 | |
| Reset | Jun 7, 2024 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Dec 7, 2023 | Jun 7, 2024 |
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to 2 years |
| WHO categories COVID-19 | Incidence of no suspicion, possible, probable and proven COVID-19 cases in the past 6 months PWH cohorts from Ukraine and the Netherlands. | Up to 2 years |
| WHO disease severity COVID-19 | Proportion of COVID-19 patients according to the severity of COVID-19 on an adapted World Health Organisation 5 point disease severity scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal) in people with HIV cohorts from Ukraine and the Netherlands. | Up to 2 years |
| Seroprevalence | Anti-SARSCOV2 seroprevalence in PWH cohorts from Ukraine and the Netherlands | Up to 2 years |
| NPV/PPV WHO categories COVID19 | Positive and negative predictive value of the WHO COVID-19 case probability categories on anti-SARSCOV2 serology in PWH cohort from Ukraine | Up to 2 years |
| Treatment | Description of COVID-19 therapeutic management in PWH cohorts from Ukraine and the Netherlands | Up to 2 years |
| Predictors for COVID-19 | Predictor variables for having clinical COVID-19 in PWH cohorts from Ukraine and the Netherlands according to 1) sex, 2) age categories (<50, 50-70, >70), 3) ART (LPV/r vs other and TDF containing vs non-TDF containing regimens), 4) most recent CD4+T-cell 5) HIV-RNA suppressed (<=50 / >50), 6) prior TB, 7) prior BCG, 8) HIV transmission group, 9) comorbidities (0 vs 1 vs >1). | Up to 2 years |
| Predictors for COVID-19 severity | Predictor variables for the highest score on an ordinal scale for COVID-19 severity according to the adapted 5point WHO severity scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal) in PWH cohorts from Ukraine and the Netherlands according to 1) sex, 2) age categories (<50, 50-70, >70), 3) ART (LPV/r vs other and TDF containing vs non-TDF containing regimens), 4) most recent CD4+T-cell 5) HIV-RNA suppressed (<=50 / >50), 6) prior TB, 7) prior BCG, 8) HIV transmission group, 9) comorbidities (0 vs 1 vs >1) | Up to 2 years |
| PPV/NPV WHO categories COVID-19 | Positive and negative predictive value of the WHO COVID-19 case probability categories in the prior 3 months on anti-SARSCOV2 serology in PWH cohort from Ukraine | Up to 2 years |
| Effect of socio-economic status by questionnaire on COVID-19 incidence | Evaluate the impact of social economic status on COVID-19 incidence. | Up to 2 years |
| Effect of socio-economic status on COVID-19 severity | Evaluate the impact of social economic status on COVID-19 severity according to WHO 5 point scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal) | Up to 2 years |
| Symptoms | Describe symptoms associated with COVID probability in PWH cohorts from Ukraine and the Netherlands | Up to 2 years |
| Rapid Ag test | Evaluate the PPV/NPV of the rapid antigen test in PWH with symptoms suspected of COVID-19 in Ukraine and the Netherlands | Up to 2 years |
| Lviv |
| Ukraine |
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |